COV-BT Ire study: safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with brain tumors

BACKGROUND: The BNT162b2 vaccine conferred 95% protection against COVID-19 in people aged 16 years or older. OBJECTIVE: The aim of this observational study was to evaluate safety and efficacy of vaccine in patients affected by primary brain tumor (PBT). METHODS: We proposed COVID-19 vaccine to all p...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanzilli, Antonio, Pace, Andrea, Ciliberto, Gennaro, La Malfa, Antonia Marina, Buonomo, Valentina, Benincasa, Dario, Biscu, Annamaria, Galiè, Edvina, Villani, Veronica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Covid-19
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994182/
https://www.ncbi.nlm.nih.gov/pubmed/35397014
http://dx.doi.org/10.1007/s10072-022-06054-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994182/
https://www.ncbi.nlm.nih.gov/pubmed/35397014
http://dx.doi.org/10.1007/s10072-022-06054-3

Ejemplares similares